Drug intelligence / Profile preview

IMX114

Development stage: Preclinical
Lead developer: Imunexus
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

IMX114 is a preclinical-stage cell therapy being developed by Imunexus. It utilizes the company's proprietary Imunexin platform—small, stable protein scaffolds derived from human proteins—to enhance mesenchymal stem cells (MSCs). By engineering MSCs to express or carry Imunexins, the therapy aims to improve the targeting, stability, or therapeutic potency of the stem cells. The program is currently partnered with an undisclosed global pharmaceutical company for further development.

Beyond the preview

Go deeper on IMX114.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMX114.

Explore the full profile